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ABSTRACT
Circular RNAs (circRNAs) are a novel type of universal and diverse endogenous 
noncoding RNAs (ncRNAs) and they form a covalently closed continuous loop without 
5′ or 3’ tails unlike linear RNAs. Most circRNAs are presented with characteristics 
of abundance, stability, conservatism, and often exhibiting tissue/developmental-
stage-specific expression. CircRNAs are generated either from exons or introns by 
back splicing or lariat introns. CircRNAs play important roles as miRNA sponges, gene 
transcription and expression regulators, RNA-binding protein (RBP) sponges and 
protein/peptide translators. Emerging evidence revealed the function of circRNAs in 
cancer and may potentially serve as a required novel biomarker and therapeutic target 
for cancer treatment. In this review, we discuss about the origins, characteristics and 
functions of circRNA and how they work as miRNA sponges, gene transcription and 
expression regulators, RBP sponges in cancer as well as current research methods 
of circRNAs, providing evidence for the significance of circRNAs in cancer diagnosis 
and clinical treatment.
INTRODUCTION
Over 70% of the human genome is found actively 
transcribed, but protein-coding genes only account for 
1~2% of the human genome, whereas the vast majority 
of transcripts are noncoding RNAs (ncRNAs) [1]. 
ncRNA can be divided into two major groups, including 
housekeeper ncRNAs, namely ribosomal RNA (rRNA), 
transfer RNA (tRNA), small nuclear RNA (snRNA) and 
small nucleolar RNA (snoRNA), as well as regulatory 
ncRNAs. Regulatory ncRNAs can be categorized 
according to the length, including small noncoding 
RNAs with transcripts shorter than 200 nucleotides like 
microRNAs (miRNAs), snRNAs, piwi-interacting RNA 
(piRNAs), small interfering RNA (siRNAs) and others, 
as well as long noncoding RNAs (lncRNAs) whose 
transcripts longer than 200 nucleotides [2]. Circular RNAs 
(circRNAs) are a naturally occurring class of noncoding 
RNAs having been paid more and more attention. They 
form a covalently closed continuous loop without 5′ caps 
and 3′ tails, which make themselves resistant to RNase 
R activity and more stable than liner RNAs [3]. It was 
more than two decades ago that circRNA was first found 
by Nigro et al. [4], but it was thought to be molecular 
flukes or artifacts of aberrant RNA splicing with no 
functions [5]. Only recently, with the rapid development of 
high-throughput RNA sequencing (RNA-Seq) technology 
and bioinformatics method, circRNAs are more and 
more extensively investigated and their important roles 
as miRNA sponges [2, 6, 7], gene transcription and 
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expression regulators [7, 8], and RNA-binding proteins 
(RBP) sponges [9–11] are uncovered. Furthermore, 
numerous of studies have confirmed the function of 
circRNAs in tumor cell proliferation, migration and 
invasion, which may potentially serve as a required novel 
biomarker and therapeutic target for cancer treatment 
[12–14].
In this review, we will first discuss about the 
origins, characteristics and functions of circRNA. Then 
we talk about how they work as miRNA sponges, gene 
transcription and expression regulators, RBP sponges in 
cancer and have a briefly introduction of current research 
methods of circRNAs in cancer, providing evidence for 
the significance of circRNAs in cancer diagnosis and 
clinical treatment. 
Origins and public databases of circRNAs
There are mainly three categories of circRNAs 
according to multiple biogenesis patterns (Figure 1): 
exonic circRNAs (ecircRNAs) [7], retained-intron 
circRNAs or ElciRNAs [8] and circular intronic RNAs 
(ciRNAs) [9]. It has been reported that circRNAs are 
generated by both canonical and noncanonical splicing, 
which are quite different from the canonical splicing 
linear RNAs. Among circRNAs, ecircRNAs are the most, 
accounting for more than 80% of identified circRNAs. 
Jeck et al. [7] first put forward two models of ecircRNA 
formation: lariat-driven circularization and intron-
pairing-driven circularization. Emerging evidence has 
revealed that circRNA molecules are mainly generated by 
a process called back-splicing, where downstream exons 
are spliced to upstream exons in reverse order [15].That 
is to say, a splice donor site joins to a splice acceptor site 
upstream in the primary transcript, producing a circular 
transcript. It is believed that exon circularization depends 
on flanking intronic complementary sequences and 
alternative formation of inverted repeated Alu pairs which 
may help determine the production rate of circRNAs [15]. 
Usually, introns between the encircled exons are spliced 
out, but in some circumstances, they are retained which 
called retained-intron circRNAs or ElciRNAs [10]. The 
origine of ciRNAs lies on a consensus motif containing a 7 
nucleotide (nt) GU-rich element near the 5′ splice site and 
an 11 nt C-rich element near the branchpoint site.
Besides, there is another model of circRNA 
biogenesis depend on RBPs. Splicing factors Quaking 
(QKI) [17] and Muscleblind (MBL) [18], served as a 
bridge linking two flanking introns close together, are 
capable to promote the formation of circRNAs. On the 
contrary, Li et al. [10] reported that RNA-editing enzyme 
ADAR1 could abolish circRNA formation by binding to 
double-stranded RNA to melt the stem structure. These 
findings indicate that RBPs play critical roles in activating 
circularization by bridging complementary sequences and 
inhibiting canonical splicing. However, further researches 
are required to elucidate the detailed mechanisms of 
circRNAs biogenesis.
Currently, there are several online databases 
(Supplementary Table 1) which collect circRNAs from 
GenBank annotations or published articles. Some ncRNAs 
in the database have been experimentally proved, some are 
purely computational predictions and some are annotated 
as ncRNAs based on the open reading frame (ORF) 
predicted size. These databases make us better investigate 
and understand circRNAs and their association with 
diseases.
Characteristics of circRNAs
Emerging evidence revealed several highlighted 
characteristics of circRNAs: 1) Abundance: Salzman et al. 
[27] first put forth that circRNAs are the most universal 
molecules exceed that of related linear mRNAs distributed 
in human cells; 2) Stability: CircRNAs presented with 
more stable property than linear mRNAs due to their 
covalently closed loop structures which confer them 
resistant to RNase R [27]. It is reported that the average 
half-life of circRNAs in most species is more than 48 h, 
while the half-life of mRNAs on average is about 10 h 
[28]; 3) Conservatism: circRNAs are highly conserved in 
different species. For example, many circRNAs can be 
detected in both humans and mice including Drosophila 
[7, 29]; 4) Location: ecircRNAs making up majority of 
circRNAs are predominantly cytoplasmic and probably 
possess miRNA response elements (MREs) [2, 30]. 
Intronic circRNAs, namely ciRNAs and EIciRNAs, are 
primarily located in the nucleus in eukaryotes and may 
take part in gene expression regulation at the transcription 
or post-transcription level [7, 9]; 5) CircRNAs often 
exhibit tissue/developmental-stage specific expression. 
For example, circRNAs expressed high in the mammalian 
brain, especially in the synapses, and during neuronal 
differentiation circRNAs are dynamically up-regulated 
[31]; 6) Some circRNAs contain miRNA binding sites and 
can competitively attenuate endogenous miRNA-mediated 
activities [7].
Functions of circRNAs
CircRNAs can serve as miRNA sponges, gene 
transcription and expression regulators, RBP sponges and 
protein/peptide translators by affecting the gene expression 
level from the transcription or post-transcription level 
(Figure 2). 
CircRNAs as miRNA sponges
As endogenous RNAs (ceRNAs), circRNAs can 
negatively regulate miRNAs activities by competing for 
miRNA-binding sites [2, 6]. The most representative 
is the human circRNA cerebellar degeneration-related 
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protein 1 transcript (CDR1as) / ciRS-7, which contains 
74 selectively conserved miRNA target sites, serving 
as miR-7 sponge. ciRS-7 originates from the transcript 
antisense to the CDR1 gene and is sensitive to miR-671, 
which can be endonucleolytically cleaved via binding to 
miR-671 in an miR-7 target site Argonaute2 (AGO2)-
dependent manner. Therefore, by cleavage of ciRS-7, 
miR-7 is transported to a subcellular location where miR-
7 is released by miR-671 activity. It has been confirmed 
that overexpression of circRNA CDR1 /ciRS-7 increased 
the expression of miRNA target genes, while knockdown 
of it has an opposite effect. Moreover, the sex-determining 
region Y (Sry) and the testis-specific circRNA, serves as 
the miR-138 sponge [6]. At present, acting as miRNA 
sponges is the main function of some circRNAs. 
CircRNAs as gene transcription and expression 
regulators
Accumulating evidence has revealed that circRNAs 
play a pivotal role in post-transcriptional and gene 
expression regulation. It is shown that EIciRNAs such as 
circEIF3J, circPAIP2 are mainly localized in the nucleus, 
interacting with U1 small nuclear ribonucleoprotein 
particle (U1 snRNP) and RNA polymerase II (Pol II) to 
enhance the transcription of their parental genes [10, 32].
Additionally, circular intronic RNA (ciRNA) ci-ankrd52 
is related with elongation Pol II machinery and positively 
regulates Pol II transcription by largely accumulating to its 
transcription sites. Knockdown of ci-ankrd52 could reduce 
the expression of their parental genes [9]. These data suggests 
that EIciRNAs and ciRNAs may regulate transcription in 
the nucleus while exonic ecircRNAs may possibly serve as 
miRNA sponges in the cytoplasm.
CircRNAs as RBP sponges 
RBPs are involved in a variety of bioactivities 
such as cell proliferation, differentiation, motility, 
apoptosis, senescence and cellular responses to oxidative 
stress through post-transcriptional regulation like RNA 
alternative splicing, stability, transport and translation 
[33, 34]. Previous studies indicated that circRNAs could 
serve as RBP sponges by stably associated with Argonaute 
(AGO) proteins [6], RNA QKI [17], MBL [18], Pol II [9], 
eukaryotic initiation factor 4A-III (EIF4A3) [35] and so 
Figure 1: Possible biogenesis patterns of circRNAs. (A) Lariat-driven circularization. ecircRNA or EIciRNA are generated by 
exon skipping event where 5′ exon attacks 3′ splice site, forming a lariat structure containing the skipped exons 2 and 3 as well as an 
mRNA consisting of exons 1 and 4. (B) Intron-pairing-driven circularization. circRNA or EIciRNA are formed by removed or retained 
introns from direct base-pairing of the introns flanking inverted repeats or ALU elements. (C) ciRNAs. ciRNAs lies on a consensus motif 
containing a GU-rich element (red dot) near the 5′ splice site and an C-rich element (blue dot) near the branchpoint site, which are capable 
for an intron to escape debranching and become a stable circRNA. (D) circRNA biogenesis depends on RBPs. Serving as a bridge linking 
two flanking introns close together, RBPs are capable to promote the formation of circRNAs by binding to sequence motifs of flanking 
introns. A circRNA or an EIciRNA is generated due to the retention of internal introns. (E) Intergenic circRNA. Because of their resistance 
to RNase R, ecircRNAs are extraordinary stable and are always located in the cytoplasm, while ciRNAs and EIciRNAs are predominately 
located in the nucleus.
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on to form large RNA-protein complexes (RPCs). These 
RPCs could regulate the pool of RBPs or small RNAs and 
then interact with the liner RNA counterparts [27]. Besides, 
through analysis of RBP binding sites on human circRNAs 
by a new web tool, CircInteractome, exceptionally high 
density of binding sites of circRNAs for a given RBP 
are found [22]. For example, hsa_circ_0024707 acts as 
a sponge for AGO2 with 85 predicted positions, and the 
mature hsa_circ_0000020 contains several RBPs binding 
sites such as FMRP (10 sites) and HuR (6 sites) [35].
CircRNAs as protein/peptide translators
It was reported that some circRNAs containing 
internal ribosome entry site elements (IRES) [36] or 
prokaryotic ribosome-binding sites [32] could encode 
proteins unlike their canonical counterparts. There is 
a circRNA database, named circRNADb, containing 
32,914 human exonic circRNAs which may offer detailed 
information of the circRNAs, including genome sequence, 
ORF and IRES to users for prediction of the translatability 
of certain circRNAs [37]. Currently, Yang et al. [38] 
first reported that N6-methyladenosine (m6A), the most 
abundant base modification of RNA, promotes efficient 
initiation of protein translation from circRNAs in human 
cells. They discovered that consensus m6A motifs are 
enriched in circRNAs and a single m6A site is sufficient 
to drive translation initiation. The m6A-driven translation 
is initiated by eIF4G2 and m6A reader YTHDF3, and is 
enhanced by methyltransferase METTL3/14, inhibited 
by demethylase FTO, and up-regulated upon heat shock. 
Furthermore, m6A-driven translation of circRNAs is 
revealed to be widespread and hundreds of endogenous 
circRNAs have translation potential, suggesting a role 
of circRNA-derived proteins in cellular responses to 
environmental stress.
CircRNAs in cancer
Accumulating evidence has revealed that circRNAs 
are correlated with various human diseases such as 
atherosclerosis [39], Alzheimer’s disease [40], Parkinson’s 
disease, diabetes [41] and especially cancers. Numerous 
investigations have been carried out to explore the aberrant 
circRNAs expressions in tumorogenesis, which may be 
considered as diagnostic and therapeutic biomarkers for 
cancer (Supplementary Table 2).
CircRNAs as miRNA sponges in cancer
The role of circRNAs as a miRNA sponge is the 
main mechanism of circRNAs in cancer. The most 
Figure 2: Functions of circRNA. (A) CircRNA as a miRNA sponges. CircRNAs can negatively regulate miRNAs activities by 
competing for miRNA-binding sites (B) CircRNA as RNA-binding protein (RBP) sponges. CircRNAs can bind RPBs to form RNA-protein 
complex (RPC) and then interact with the linear transcript of gene. (C) CircRNAs as protein translators. circRNAs which contain internal 
ribosome entry site elements (IRES) or prokaryotic ribosome-binding sites could generate functional proteins/peptide.
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well-known miRNA sponge is CDR1as/ciRS-7, which 
comprises more than 70 miR-7 binding sites and serves 
as a miR-7 sponge. Accumulating evidence has revealed 
that miR-7 acts as a tumor suppressor in a variety of 
cancers, such as hepatocellular carcinoma (HCC) [42], 
gastric cancer (GC) [43], colorectal cancer (CRC) [44], 
breast cancer [45], cervical cancer [46], lung neoplasm 
[26], tongue cancer [47], Schwannoma tumor [48]. Chou 
et al. [49] found that in lung cancer tumorogenesis, 
ciRS-7 could increase the expression of miR-7 target 
oncogenes and decrease the tumor suppression genes to 
significantly reduce the activity of miR-7. Many cancer-
related pathways have been involved in miR-7-associated 
regulations, such as directly down-regulated oncogenic 
factors epidermal growth factor receptor (EGFR) [50], 
mammalian target of rapamycin (mTOR) [42], Yin Yang 
1 (YY1) [44], insulin receptor substrate-1 (IRS-1) and 
insulin receptor substrate-2 (IRS-2) [50], phosphoinositide 
3-kinase catalytic subunit delta (PIK3CD) [51], Raf1 
[51], Ack1 [48], P21-activated kinase-1 (Pak1) [52] and 
PA28γ [53].Moreover, miR-7 indirectly down-regulates 
signal transducer and activator of transcription3 (STAT3) 
by down-regulating histone-lysine N-methyltransferase1 
(SETDB1), resulting in epithelial to mesenchyme transition 
(EMT), suppressing breast cancer stem cells invasion and 
metastasis [54]. Ning et al [55] found that miR-7 directly 
targets and attenuates p65 and then activates NF-κB to 
inhibit HCC metastasis. ciRS-7 acts as a risk factor of 
hepatic microvascular invasion in HCC [56].
 But on the contrary, Honegger et al. [57] 
presented that viral oncogene E6/E7 is related to miR-
7 overexpression in HPV-positive HeLa cell line and 
Nakagawa et al. [58] revealed miR-7 expression is 
increased in advanced colorectal cancers. These examples 
demonstrate that the miR-7/miR-671/ciRS-7 axis possibly 
participates in cancer-associated biological processes by 
either serve as a cancer suppressor or promoter largely 
relied on the expression level of miRNA target genes.
Additionally, cir-ITCH as sponges of miR-7 and 
miR-20a is involved in colorectal cancer [59]. And cir-
ITCH as miR-7, miR-17 and miR-214 sponges may have 
a tumor suppressive role in esophageal squamous cell 
carcinoma (ESCC) [12] while cir-ITCH as miR-7 and miR-
214 sponges takes part in lung cancer. It has shown that the 
role of cir-ITCH in tumor formation and chemosensitivity 
through miRNA regulation is mediated by Wnt/β-catenin 
signaling pathway via ubiquitination and degradation of 
phosphorylated Dvl2 [59, 60]. Another circHIPK3 has 
been identified to be associated with cancer progression 
by binding miR-124, which exhibited the most prominent 
binding effect [61]. Foxo3 circular RNA (circ-Foxo3) 
increases Foxo3 translation and further suppresses tumor 
growth, cancer cell proliferation and survival by acting 
as a sponge of potential miRNAs [62]. CircRNA_1093, 
which contains 4 miR-342-3p binding sites, is implicated 
in BRCA1 expression in breast cancer [63, 64]. 
CircZEB-1.17, circ-ZEB1.19, circZEB1.33 and circZEB1.5 
are down-regulated in the lung cancer as the miR-200 
sponge [21]. Hsa_circ_001569 positively regulates cell 
proliferation and invasion of colorectal cancer by acting as 
a miR-145 sponge. It inhibits the transcriptional activity of 
miR-145 without influencing its expression level, resulting 
in the upregulation of target genes of miR-145, including 
E2F5, BAG4, and FMNL2 [13]. 
Currently, Zheng et al. [65] found that circ-TTBK2 
was up-regulated in glioma tissues and cell lines acted 
as miR-217 sponge in a sequence-specific manner but 
not linear TTBK2. In addition, upregulated circ-TTBK2 
decreased miR-217 expression and there was a reciprocal 
negative feedback between them in an Argonaute2 
(AGO2)-dependent manner. As miRNA sponges, 
circRNAs provide us a novel insight of cancer treatment, 
but there remain quantities of unknown circRNAs and 
specific circRNA-miRNA-gene regulatory mechanisms 
in cancer initiation and progression which need further 
investigations. 
CircRNAs as transcription regulators in cancer
As mentioned above, certain circRNAs like ci-
mcm5 and ci-sirt7 can enhance the transcription of 
their parental genes which suppress or promote cancer 
progression [9, 66]. For instance, overexpression of 
MCM5 is believed to be involved in both colorectal 
cancer and oral squamous cell carcinoma, predicating poor 
outcomes [67, 68]. Inversely, low expression of SIRT7 is 
related to aggressive tumor phenotype and poor prognosis 
in pancreatic ductal adenocarcinoma (PDAC) [69]. 
cZNF292 is found to suppress glioma cells proliferation 
and vascularization by reducing the expression of cellular 
Cyclin A, p-CDK2, CDK2, β-catenin, p-STAT3(Tyr705) 
and p-STAT5 (Tyr694). And downregulation of cZNF292 
lead to decreased transcription of E2F1, NF-κB, Sp1, HIF-
1, AP-1, STAT3, and STAT5, inhibiting tube formation of 
tumor cells [70]. Therefore, circRNAs that are considered 
as a type of alternative splicing isoforms may play a key 
role in regulating gene expression, leading to cancer-
related dysregulation. 
CircRNAs as RBP sponges in cancer
It has been revealed that RBPs such as QKI, 
AGO, Pol II and MBL can bind to circRNAs and RBP 
misregulation of gene transcription or expression plays 
an important role in cancer progression [71, 72]. The 
most widely studied is the RNA-binding protein quaking 
5 (QKI-5), which has been recognized as a novel tumor 
suppressor in many cancers, including lung cancer and 
prostate cancer [73, 74]. CircRNAs themselves are 
regulated during epithelial-mesenchymal transition 
(EMT), which is involved in the progression of cancer 
metastasis. The up-regulation of circRNAs during EMT 
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implies they carry out important functions in EMT 
[17]. But circRNAs formation is regulated by QKI 
proteins, providing a novel perspective to QKI-mediated 
circRNAs therapeutic strategies in cancer. Meanwhile, 
AGO proteins was also revealed to be ectopically over-
expressed in cancer and closely related to the cancers 
development via miRNAs-dependent or independent 
pathways [75]. These observations suggest that circular 
RNAs and RBPs might interact with each other to have 
effect on tumorogenesis.
In addition, circ-Foxo3 plays a role in cell cycle 
suppressor by binding to the cell cycle proteins cyclin-
dependent kinase 2 (CDK2) and cyclin-dependent kinase 
inhibitor 1 (or p21), forming a ternary complex to inhabit 
the function of CDK2 and block cell cycle progression. 
CDK2 could interacts with cyclin A and cyclin E to 
facilitate cell cycle entry, while p21 could inhibit these 
interactions and arrest cell cycle progression [76]. As 
CDK2 is associated with multiple cancers, like breast 
cancer [77], colorectal cancer [78], non-small cell lung 
cancer (NSCLC) [79], hence, circ-Foxo3 also carry 
out functions in cancers above by forming circ-Foxo3-
p21-CDK2 ternary complex. What’s more, circ-Foxo3 
can also bind to proteins ID1, E2F1, FAK, and HIF-1α, 
retaining them in the cytoplasm and promoting cardiac 
senescence [76].These findings indicate that circRNAs 
may take part in cancer progression by binding to partners. 
Recently, Abdelmohsen et al. [80] newly identified 
some circRNAs binding HuR in human cervical carcinoma 
HeLa cells. One of the most prominent HuR target 
circRNAs was hsa_circ_0031288, renamed CircPABPN1 
as it arises from the PABPN1 pre-mRNA. Further 
analyses revealed that HuR did not influence CircPABPN1 
abundance while high levels of CircPABPN1 suppressed 
HuR binding to PABPN1 mRNA, providing the first 
example of competition between a circRNA and its 
cognate mRNA for an RBP that affects translation. 
CircRNAs as potential biomarkers in cancer
As mentioned above, circRNAs have the 
characteristics of abundant, conservative across species, 
stably expressed in saliva, blood, and exosomes, exhibiting 
tissue/developmental-stage specific property, which meet 
the requirement of promising cancer biomarkers. Besides, 
circRNAs are more likely to be detected than miRNAs 
whose number is relatively small. In addition, the way of 
testing circRNAs by RT-PCR and in-situ hybridization 
is more sensitive and specific than detecting proteins by 
an antigen-antibody reaction. So circRNAs may have the 
advantage of serving as potential cancer biomarkers. There 
are already various circRNAs recognized as potential 
biomarkers. For example, circ_100855 predominately up-
regulated and circ_104912 significantly down-regulated in 
laryngeal squamous cell cancer tissues (LSCC) tissues, and 
their expressions are remarkably associated with tumor 
stage and neck nodal metastasis, implying a potential 
novel biomarker in LSCC tumorigenesis [81]. By using 
qRT-PCR, hsa_circ_100855 were detected as the most 
up-regulated circRNA and hsa_circ_104912 as the most 
down-regulated circRNA, implying that patients with T3-4 
stage, neck nodal metastasis or advanced clinical stage 
had higher hsa_circ_100855 expression and lower hsa_
circ_104912 expression [81]. Analogously, circ_002059 
down-regulated in gastric cancer is related with distal 
metastasis, TNM stage, gender, and age, serving as a 
pivotal role for the diagnosis of gastric cancer [14]. 
Besides, hsa_circ_0000190 [82], hsa_circ_0000096 [83], 
and circPVT1 [84] are newly found to be promising 
gastric cancer biomarkers. Similarly, hsa_circ_0001649 
[85] and hsa_circ_0005075 [86] are regarded as critical 
biomarkers for the physiological and pathological 
processes of hepatocellular carcinoma. In addition, 
hsa_circ_001988 [87] as well as hsa_circ_0000069 [88] 
is involved in colorectal cancer progression. Zhu et al.
[89] recently characterized the circRNA expression 
profile from three paired colorectal cancer and adjacent 
normal tissues by human circRNA array, and validated 
one circRNA generated from Exon 5-11 of BANP 
gene, termed circ-BANP. The results demonstrated that 
dysregulated circ-BANP appears to have an important 
role in colorectal cancer cells and could serve as a 
prognostic and therapeutic marker for colorectal cancer. 
ciRS-7 was found significantly up-regulated in colorectal 
cancer tissues and is a promising prognostic biomarker in 
colorectal cancer patients, serving as a therapeutic target 
for reducing oncogenes EGFR-RAF1 activity [90]. Li et al. 
[91] examined serum exosome RNA sequencing datasets 
from 11 patients with colorectal cancer and normal serum, 
identifying that 67 circRNAs were missing as well as 257 
new circRNA species were detected in colorectal cancer 
patients. Among the newly detected circRNAs, 48 genes 
for 53 circRNAs were remarkably up-regulated. Recently, 
circBRAF was found to be significantly down-regulated 
in glioma patients with high pathological grade (WHO III 
& IV) than those with low grade (WHO I & II) (P < .001). 
CircBRAF could severe as a biomarker for predicting 
pathological grade and prognosis in glioma patients [92]. 
What’s more, hsa_circ_0067934 is demonstrated to be 
up-regulated in ESCC tissues and represents a novel 
potential biomarker and therapeutic target of ESCC [93]. 
In bladder cancer, overexpression of circTCF25 promotes 
proliferation and migration might be through circTCF25-
miR-103a-3p/miR-CDK6 pathway, suggesting a new 
promising marker for bladder cancer [94]. Li et al. [95] 
used microarray to identify dysregulated circular RNAs 
in PDAC patients and demonstrated clusters of aberrantly 
expressed circRNAs in PDAC, providing new potential 
targets for the future treatment of PDAC and novel insights 
into PDAC biology. Moreover, a total of 322 circRNAs 
were aberrantly expressed between cutaneous squamous 
cell carcinoma and non-lesional skin biopsies. The 
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same cohort also discovered 71 differentially expressed 
circRNAs in basal cell carcinoma [96].
Recently, well-established cancer-associated 
chromosomal translocations gave rise to fusion circRNAs 
(f-circRNA) which were produced from transcribed exons 
of distinct genes affected by the translocations. Guarnerio 
et al. [97] found that f-circRNA plays an active role in 
favoring leukemia progression when coupled with other 
oncogenic stimuli. Alhasan et al. [98] found that circRNAs 
are enriched in human platelets 17- to 188-fold relative 
to nucleated tissues because liner RNAs are more likely 
to be degraded. Besides, circRNAs can also participate in 
platelets relative miRNA regulations acting as endogenous 
competitive RNAs [99]. f-circM9 and f-circPR are formed 
by the PML/RARa and MLL genes fusion and knockouts 
of f-circM9 and f-circPR could lead to apoptosis of 
quantities of tumor cells and increases their sensitivity to 
drugs, such as arsenic as well, suggesting that f-circM9 
and f-circPR play a oncogenic role in hematological 
malignancy [97]. Taken together, aberrantly expressed 
circRNAs in human cancers can be employed as a new 
class of diagnostic, prognostic and therapeutic biomarkers.
CircRNAs with microarray in cancer
Over the past decades, the gene expression microarray 
has been recognized as a useful and feasible approach to 
profile the molecular signatures, including circRNAs. The 
experiment workflow of microarray expression profile of 
circRNAs (Figure 3) is quite different from the liner RNAs. 
For example, Su et al. [100] executed microarray analysis 
and bioinformatic tools to investigate the role of circRNAs 
in the radioresistance of esophageal cancer. Results showed 
that there was more than 400 target genes enrichment 
on Wnt signaling pathway and circRNA_001059 and 
circRNA_000167 were the two largest nodes in circRNA/
microRNA co-expression network. In addition, to explore 
lncRNAs and circRNAs expression profiling and their 
biological functions in bladder cancer tumorigenesis, Huang 
et al. [101] used microarray to identify aberrantly expressed 
circRNAs, lncRNAs and mRNAs. GO and KEGG pathway 
enrichment analyses were executed to determine the 
principal functions of the significantly deregulated genes 
and bioinformatics methods were constructed to explore 
correlated expression networks including ceRNA, cis 
regulation, coding-noncoding co-expression (CNC), 
lncRNAs-transcription factor (TF)-mRNA. Results 
indicated that lncRNA H19 and circRNA MYL could 
bind competitively with miRNA-29a-3p, increasing target 
gene DNMT3B, VEGFA and ITGB1 expressions. Hence, 
lncRNAs and circRNAs could play a critical role in the 
pathogenesis and development of bladder cancer. Recently, 
Zhang et al. [102] identified 46 differently expressed 
circRNAs between cancer and adjacent normal tissues by 
using microarray. Then a four-circRNA-based classifier 
was constructed to evaluate the early recurrence of stage 
III gastric cancer after radical surgery, whose area under 
the receiver operator characteristic curve (ROC) reached to 
0.763. Currently, microarray was used to screen differently 
expressed circRNAs and mRNAs in gastric cancer and 
adjacent tissues. CircRNAs regulating the expression 
of target genes through interactions with miRNAs via 
a variety of mechanisms might become new molecular 
biomarkers for gastric cancer in the future [103]. Besides, 
our research team used bioinformatics method combined 
with microarray to analysis associated circRNAs in kidney 
cancer (Figure 4), which owned intellectual property rights.
CircRNA with RNA-Seq in cancer
Rapid development of high-throughput RNA 
sequencing (RNA-Seq) technology and bioinformatics 
Figure 3: Workflow of microarray analysis of circRNAs.
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method make it possible to identify and quantify 
circRNAs in samples of interest accurately, gaining 
more insights of the expression dynamics and biological 
functions of circRNAs. Since circRNAs are non-
polyadenylated, poly (A)-selected RNA-Seq data cannot 
be used for circRNA discovery. Now RNA-Seq is wildly 
constructed in the study of circRNAs. For example, 
Ahmed et al. [104] performed paired-end RNA sequencing 
of primary sites, peritoneal and lymph node metastases 
from three patients with stage IIIC ovarian cancer and 
revealed that a significantly larger number of circRNAs 
were differentially expressed between tumor sites than 
mRNAs and had a more robust expression pattern than 
mRNA forms. Thus circRNAs may be more suitable as 
biomarkers for cancer treatment and prognosis. Hsiao et al.
[105] used RNA-Seq data from matched normal and tumor 
colon tissue samples to identify numerous circRNAs and 
CircCCDC66 was found to be significantly elevated in 
polyps and colon cancer, which promoted colon cancer 
progression, metastasis and poor prognosis. Recently, Yao 
et al. [106] demonstrated ZKSCAN1, which is expressed 
in both linear and circular (circZKSCAN1) forms of RNA 
Figure 4: Bioinformatics analysis combined with microarray in kidney cancer. 
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in human HCC tissues and cell lines, was significantly 
lower in the HCC samples compared with that in matched 
adjacent non-tumorous tissues. But RNA-seq revealed that 
ZKSCAN1 mRNA mainly regulated cellular metabolism, 
while circZKSCAN1 mediated several cancer-related 
signaling pathways, including PI3K pathway, migration 
pathway, actin cytoskeleton pathway, adhesion pathway 
and cytokine interaction pathway, suggesting ZKSCAN1 
mRNA and circZKSCAN1 may cooperate closely with 
one another to inhibit growth, migration, and invasion 
of HCC. Furthermore, cirZKSCAN1 might be a useful 
marker for the diagnosis of HCC. 
CONCLUSIONS
It has been more than two decades since circRNAs 
were first discovered. Though circRNAs were originally 
thought to be splicing mistakes, but with the development 
of high-throughput sequencing technologies and 
bioinformatics method, circRNAs are increasingly 
investigated. In this review, we first discuss about the 
origins, characteristics and main functions of circRNAs. 
Based on the function as miRNA sponges, translation and 
expression regulators and RBP sponges, circRNAs play an 
important role in cancer and we talk about current research 
methods of circRNAs in cancer, providing evidence for 
the significance of circRNAs in cancer diagnosis and 
clinical treatment.
Perspective
With the advancement of study method, the 
investigations of circRNAs are drawing more and 
more attention. The functions of circRNAs as miRNA 
sponges, transcriptional regulators and RBP sponges 
are increasingly recognized and the roles of circRNAs 
in biogenesis and functional mechanisms in numerous 
diseases including cancers are becoming the focus of 
study. These findings elucidate the physiological and 
pathological processes of a number of circRNAs which 
may be regarded as novel diagnostic biomarkers and 
potential therapeutic targets in cancer, but there remain 
vast majorities of circRNAs to be investigated and specific 
molecular mechanisms to be explored. Compared with 
long noncoding RNAs (lncRNAs) and miRNA, circRNAs 
has the advantage of high stability, which can be regarded 
as promising clinical biomarkers for diagnosis, prognosis 
and therapy. In addition, since the first report of abundant 
presence of circRNAs in exosomes, the studies of 
circRNAs are coming into a new sight [87]. Exosomes 
are small membrane vesicles of endocytic origin secreted 
by most cell types [97]. Reports showed that exosomal 
circRNAs may be regulated by changes of associated 
miRNA levels in producer cells and may transfer 
biological activity to recipient cells. Exosomal circRNAs 
are likely to be regarded as a new class of exosome-
based cancer biomarkers and to play potential biological 
function. In future studies, with scientists’ endeavors and 
applications of new approaches, many more circRNAs 
will be well identified and potential mechanisms will 
be disclosed to improve the diagnosis and treatment of 
circRNA-related diseases.
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